Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aerie Pharmaceuticals Company

AERI
US00771V1089
A1W7RL

Price

15.25
Today +/-
+0
Today %
+0 %
P

Aerie Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aerie Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aerie Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aerie Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aerie Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aerie Pharmaceuticals Stock Price History

DateAerie Pharmaceuticals Price
11/22/202215.25 undefined
11/21/202215.25 undefined

Aerie Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aerie Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aerie Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aerie Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aerie Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aerie Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aerie Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aerie Pharmaceuticals’s growth potential.

Aerie Pharmaceuticals Revenue, EBIT and net profit per share

DateAerie Pharmaceuticals RevenueAerie Pharmaceuticals EBITAerie Pharmaceuticals Net Income
2026e384.26 M undefined-18.93 M undefined-36.34 M undefined
2025e296.29 M undefined-11.57 M undefined-22.95 M undefined
2024e233.03 M undefined-7.21 M undefined-14.79 M undefined
2023e183.08 M undefined-54.53 M undefined-63.73 M undefined
2022e138.59 M undefined-91.82 M undefined-105.98 M undefined
2021194.13 M undefined-46.35 M undefined-74.81 M undefined
202083.14 M undefined-155.69 M undefined-183.1 M undefined
201969.89 M undefined-187.49 M undefined-199.58 M undefined
201824.18 M undefined-209.74 M undefined-232.57 M undefined
20170 undefined-145.69 M undefined-145.11 M undefined
20160 undefined-96.87 M undefined-99.06 M undefined
20150 undefined-75.09 M undefined-74.36 M undefined
20140 undefined-49.97 M undefined-48.13 M undefined
20130 undefined-22.17 M undefined-31.6 M undefined
20120 undefined-14.29 M undefined-15.64 M undefined
20110 undefined-14.22 M undefined-13.42 M undefined

Aerie Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
0000000246983194138183233296384
--------187.5020.29133.73-28.8732.6127.3227.0429.73
-------95.8394.2068.6786.08-----
000000023655716700000
-14-14-22-49-75-96-145-209-187-155-46-91-54-7-11-18
--------870.83-271.01-186.75-23.71-65.94-29.51-3.00-3.72-4.69
-13-15-31-48-74-99-145-232-199-183-74-105-63-14-22-36
-15.38106.6754.8454.1733.7846.4660.00-14.22-8.04-59.5641.89-40.00-77.7857.1463.64
0.930.954.9624.0925.7829.1435.3241.6645.4345.946.3400000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Aerie Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aerie Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20112012201320142015201620172018201920202021
                     
15.12.969.6139.9136.6233.7249.7202.8309.2240.4139.8
00000002.738.45668.83
000000000090
000000010.121.127.140.41
0.10.10.61.11.944.54.57.78.316.61
15.2370.2141138.5237.7254.2220.1376.4331.8355.65
0.20.10.10.23.87.931.960.574.768.374.14
00018.313.8000000
00000000000
00000000000
00000000000
000.11.53.12.74.24.31.61.91.6
0.20.10.22020.710.636.164.876.370.275.74
15.43.170.4161159.2248.3290.3284.9452.7402431.39
                     
60.360.9000000000.05
000.160.170.240.420.60.921.061.11.14
-48.8-63.9-95.1-143.2-217.6-316.6-461.7-696.4-896-1,079.1-1,153.91
000-0.1-0.2-0.100-0.1-0.1-0.13
00000000000
11.6-366.92818.7105.3135.6227.8166.923.9-17.33
0.20.21.42.11.65.66.212.412.88.88.29
2.51.326.813.813.818.938.470.995.6116.71
00001.7000000
02.3000000000
00000000000
2.73.83.48.917.119.425.150.883.7104.4124.99
000124.2123.2123.5123.80188.7210.4234.53
00000000000
1.12.500005.66.513.463.289.21
1.12.50124.2123.2123.5129.46.5202.1273.6323.73
3.86.33.4133.1140.3142.9154.557.3285.8378448.72
15.43.370.3161.1159248.2290.1285.1452.7401.9431.39
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aerie Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aerie Pharmaceuticals's financial health and stability.

Assets

Aerie Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aerie Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aerie Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aerie Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20112012201320142015201620172018201920202021
-12-14-31-48-74-99-145-232-199-183-74
00000012566
00000000000
1-11440-113-2344-92
0113913175164676761
00002221654
00000100040
-12-14-16-33-55-79-93-152-150-64-99
0000-3-5-15-31-9-3-3
000-73918-4220-18373-18
000-731223-2652-17376-14
00000000000
0315122000030800
25071051169134135002
232831225116813513727402
-1,0000-3,00000-1,0001,0001,000-34,00000
00000000000
11-126615510605-587-114
-12.05-15.02-16.51-33.91-59.03-84.92-109.18-183.89-160.39-67.79-102.45
00000000000

Aerie Pharmaceuticals stock margins

The Aerie Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aerie Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aerie Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aerie Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aerie Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aerie Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aerie Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aerie Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aerie Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aerie Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aerie Pharmaceuticals Margin History

Aerie Pharmaceuticals Gross marginAerie Pharmaceuticals Profit marginAerie Pharmaceuticals EBIT marginAerie Pharmaceuticals Profit margin
2026e86.17 %-4.93 %-9.46 %
2025e86.17 %-3.9 %-7.75 %
2024e86.17 %-3.09 %-6.35 %
2023e86.17 %-29.78 %-34.81 %
2022e86.17 %-66.25 %-76.47 %
202186.17 %-23.88 %-38.54 %
202069.53 %-187.26 %-220.23 %
201993.09 %-268.26 %-285.56 %
201897.35 %-867.41 %-961.83 %
201786.17 %0 %0 %
201686.17 %0 %0 %
201586.17 %0 %0 %
201486.17 %0 %0 %
201386.17 %0 %0 %
201286.17 %0 %0 %
201186.17 %0 %0 %

Aerie Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Aerie Pharmaceuticals earnings per share therefore indicates how much revenue Aerie Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aerie Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aerie Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aerie Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aerie Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aerie Pharmaceuticals Revenue, EBIT and net profit per share

DateAerie Pharmaceuticals Sales per ShareAerie Pharmaceuticals EBIT per shareAerie Pharmaceuticals Earnings per Share
2026e7.78 undefined0 undefined-0.74 undefined
2025e6 undefined0 undefined-0.46 undefined
2024e4.72 undefined0 undefined-0.3 undefined
2023e3.7 undefined0 undefined-1.29 undefined
2022e2.8 undefined0 undefined-2.14 undefined
20214.19 undefined-1 undefined-1.61 undefined
20201.81 undefined-3.39 undefined-3.99 undefined
20191.54 undefined-4.13 undefined-4.39 undefined
20180.58 undefined-5.03 undefined-5.58 undefined
20170 undefined-4.12 undefined-4.11 undefined
20160 undefined-3.32 undefined-3.4 undefined
20150 undefined-2.91 undefined-2.88 undefined
20140 undefined-2.07 undefined-2 undefined
20130 undefined-4.47 undefined-6.37 undefined
20120 undefined-15.04 undefined-16.46 undefined
20110 undefined-15.29 undefined-14.43 undefined

Aerie Pharmaceuticals business model

Aerie Pharmaceuticals Inc is a US-based company specializing in the development of drugs for the treatment of eye diseases. The company was founded in 2005 by David Epstein and is headquartered in Durham, North Carolina. Aerie Pharmaceuticals aims to use innovative thinking and the latest technologies to improve the treatment of eye diseases and enhance the lives of people worldwide. They have developed several drugs that are already available on the market. Their main focus is on researching and developing eye medications, particularly those that can reduce intraocular pressure in patients with glaucoma. Their key drugs are Rhopressa and Rocklatan. In addition, they have plans to develop and market more products for the treatment of eye diseases. They collaborate with various partners including pharmaceutical distributors and pharmacies to bring their medications to the market globally. Overall, Aerie Pharmaceuticals is a leading provider of ophthalmic drugs and is dedicated to revolutionizing the treatment of eye diseases. Aerie Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Aerie Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Aerie Pharmaceuticals Revenue by Segment

Segmente2021202020192018
Product revenues, net112.13 M USD83.14 M USD69.89 M USD24.18 M USD
Licensing revenues82 M USD---

Aerie Pharmaceuticals SWOT Analysis

Strengths

Aerie Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company has a strong portfolio of innovative products that address unmet needs in ophthalmology. This gives them a competitive edge in the market and helps to attract customers and investors. Secondly, Aerie Pharmaceuticals has a robust research and development (R&D) pipeline, which allows them to continuously develop and launch new products. This helps them stay ahead of competitors and adapt to changing market trends. Additionally, the company has a talented team of professionals with extensive knowledge and experience in the pharmaceutical sector. This expertise enables them to effectively develop, manufacture, and market their products, ensuring the highest quality standards. Lastly, Aerie Pharmaceuticals has established strong partnerships and collaborations with other industry players, which provide additional resources and opportunities for growth and expansion. These collaborations help in advancing research, accessing new markets, and sharing knowledge and expertise.

Weaknesses

Despite its strengths, Aerie Pharmaceuticals Inc also faces certain weaknesses that could hinder its progress. One of the weaknesses is the high dependency on a limited number of products. If any of these key products face regulatory or market challenges, it could adversely affect the company's financial performance. Moreover, being a relatively smaller player in the industry, Aerie Pharmaceuticals may have limited resources and financial capabilities compared to its larger competitors. This might restrict their ability to invest in extensive marketing campaigns or expand their operations rapidly. Additionally, the pharmaceutical industry is highly regulated, and any changes in regulations or compliance requirements can pose challenges and additional costs for Aerie Pharmaceuticals. This might impact their ability to meet regulatory standards and could potentially delay product approvals or launches.

Opportunities

Aerie Pharmaceuticals Inc can capitalize on various opportunities available in the market. One significant opportunity is the increasing demand for ophthalmic products due to the aging population and the rising prevalence of eye diseases. By focusing on developing innovative and effective treatments for these conditions, the company can tap into a growing market. Another opportunity lies in expanding their global presence and entering new markets. Aerie Pharmaceuticals can explore partnerships or collaborations with international distributors or licensing their products to gain access to new regions. This would not only boost their revenue but also diversify their customer base. Moreover, advancements in technology provide an opportunity for Aerie Pharmaceuticals to develop and launch novel drug delivery systems or enhance their existing products. By leveraging these technological advancements, they can improve patient outcomes and differentiate themselves from competitors.

Threats

Aerie Pharmaceuticals Inc operates in an industry that faces various threats, which may impact its performance. One significant threat is the intense competition from both generic and branded pharmaceutical companies. This competition may result in pricing pressures and reduced market share for Aerie Pharmaceuticals. Additionally, the possibility of regulatory hurdles and longer approval processes can pose threats to the company's product development and launch timelines. Delays in approvals or unfavorable regulatory decisions could hinder their ability to generate revenue and impact market potential. Moreover, fluctuations in currency exchange rates or economic downturns in key markets can affect Aerie Pharmaceuticals' financial performance. These external factors are beyond their control and may pose risks to their operations and profitability.

Aerie Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aerie Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Aerie Pharmaceuticals shares outstanding

The number of shares was Aerie Pharmaceuticals in 2023 — This indicates how many shares 46.336 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aerie Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aerie Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aerie Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aerie Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Aerie Pharmaceuticals.

Aerie Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
9.50074 % Deerfield Management Company, L.P.4,695,02006/30/2022
5.95206 % BlackRock Institutional Trust Company, N.A.2,941,353118,0896/30/2022
5.50310 % The Vanguard Group, Inc.2,719,487160,0076/30/2022
4.77767 % Jefferies LLC2,361,000-15,9706/30/2022
4.23902 % Schroder Investment Management North America Inc.2,094,811-257,1836/30/2022
3.73275 % Rice Hall James & Associates, LLC1,844,627166,0186/30/2022
3.46161 % UBS Financial Services, Inc.1,710,637100,7816/30/2022
3.32645 % FundLogic SAS1,643,84606/30/2022
2.73220 % Easterly Investment Partners LLC1,350,1831,350,1836/30/2021
2.58886 % Medical Strategy GmbH1,279,34505/31/2022
1
2
3
4
5
...
10

Aerie Pharmaceuticals Executives and Management Board

Mr. Raj Kannan58
Aerie Pharmaceuticals Chief Executive Officer, Director (since 2021)
Compensation 3.52 M
Dr. Casey Kopczynski60
Aerie Pharmaceuticals Co-Founder, Chief Innovation Officer, Head of Research and External Innovation
Compensation 1.46 M
Mr. John Larocca57
Aerie Pharmaceuticals General Counsel and Secretary
Compensation 1.45 M
Dr. Benjamin Mcgraw73
Aerie Pharmaceuticals Independent Director (since 2014)
Compensation 1.34 M
Ms. Julie Mchugh57
Aerie Pharmaceuticals Independent Director
Compensation 173,669
1
2
3

Aerie Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Liquidia Stock
Liquidia
SupplierCustomer0,960,720,770,20-0,82-0,70
BioLight Life Sciences Stock
BioLight Life Sciences
SupplierCustomer0,510,290,790,380,91-
Koninklijke DSM Stock
Koninklijke DSM
SupplierCustomer0,240,550,680,260,15-0,27
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer0,13-0,36-0,11-0,05-0,71-0,51
McKesson Stock
McKesson
SupplierCustomer-0,07-0,68-0,51-0,11-0,79-0,60
Cardinal Health Stock
Cardinal Health
SupplierCustomer-0,260,570,05-0,040,32
Santen Pharmaceutical Stock
Santen Pharmaceutical
SupplierCustomer-0,48-0,200,760,320,670,26
1

Most common questions regarding Aerie Pharmaceuticals

What values and corporate philosophy does Aerie Pharmaceuticals represent?

Aerie Pharmaceuticals Inc represents values of innovation, dedication, and patient-centricity in the pharmaceutical industry. The company aims to develop and commercialize groundbreaking therapies that address unmet needs in ophthalmology. With a strong focus on research and development, Aerie Pharmaceuticals is committed to improving the lives of individuals suffering from eye diseases. By employing cutting-edge technologies and collaborating with experts, Aerie strives to advance scientific understanding and deliver effective treatments. The company's corporate philosophy emphasizes integrity, teamwork, and a mission-driven approach to revolutionize eye care. Aerie Pharmaceuticals Inc continually strives to make a positive impact on patients' vision health.

In which countries and regions is Aerie Pharmaceuticals primarily present?

Aerie Pharmaceuticals Inc primarily operates and is present in various countries and regions worldwide. The company has a global presence, with its main focus on the United States, where it is headquartered. Additionally, Aerie Pharmaceuticals Inc has commercial operations and partnerships across countries such as Canada, Europe (including the United Kingdom and Germany), Latin America, and Asia-Pacific regions. By expanding its reach internationally, Aerie Pharmaceuticals Inc aims to provide its innovative ophthalmic products and therapies to a broader patient population and improve global eye health.

What significant milestones has the company Aerie Pharmaceuticals achieved?

Aerie Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for Rocklatan®, a once-daily eye drop for the treatment of glaucoma and ocular hypertension. Aerie also achieved positive Phase 3 results for Rhopressa®, another innovative eye drop for lowering intraocular pressure. Furthermore, Aerie Pharmaceuticals Inc expanded its product portfolio through strategic collaborations and acquisitions, enhancing its research and development capabilities. With these accomplishments, Aerie Pharmaceuticals Inc has established itself as a leading pharmaceutical company specializing in the treatment of eye disorders, making significant advancements in the ophthalmic industry.

What is the history and background of the company Aerie Pharmaceuticals?

Aerie Pharmaceuticals Inc is a renowned pharmaceutical company that specializes in the discovery, development, and commercialization of innovative therapies for treating eye diseases. Established in 2005, Aerie Pharmaceuticals has a strong commitment to improving patients' lives by addressing unmet medical needs in ophthalmology. The company has achieved significant milestones, including the approval and launch of their first product, Rhopressa®, a treatment for glaucoma. With a focus on developing cutting-edge advancements in ocular health, Aerie Pharmaceuticals continues to expand its portfolio and is dedicated to enhancing vision care worldwide.

Who are the main competitors of Aerie Pharmaceuticals in the market?

The main competitors of Aerie Pharmaceuticals Inc in the market are Alcon, Allergan, and Novartis.

In which industries is Aerie Pharmaceuticals primarily active?

Aerie Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Aerie Pharmaceuticals?

Aerie Pharmaceuticals Inc operates under a distinct business model in the pharmaceutical industry. They focus on researching, developing, and commercializing innovative treatments for eye diseases. The company primarily specializes in glaucoma management and ocular surface diseases. Aerie Pharmaceuticals Inc aims to provide safe and effective therapeutics to improve patients' eye health and vision. With a strong dedication to scientific excellence and patient-centered approach, the company continues to strive for breakthroughs in the field of ophthalmology.

What is the P/E ratio of Aerie Pharmaceuticals 2024?

The Aerie Pharmaceuticals P/E ratio is -47.79.

What is the P/S ratio of Aerie Pharmaceuticals 2024?

The Aerie Pharmaceuticals P/S ratio is 3.03.

What is the Quality Investing of Aerie Pharmaceuticals?

The Quality Investing for Aerie Pharmaceuticals is 5/10.

What is the revenue of Aerie Pharmaceuticals 2024?

The expected Aerie Pharmaceuticals revenue is 233.03 M USD.

How high is the profit of Aerie Pharmaceuticals 2024?

The expected Aerie Pharmaceuticals profit is -14.79 M USD.

What is the business model of Aerie Pharmaceuticals

Aerie Pharmaceuticals Inc. is a US pharmaceutical company specialized in research, development, and marketing of drugs for the treatment of eye diseases. The company is headquartered in Durham, North Carolina and was founded in 2005. The company's activities can be divided into two main areas: research and development, and sales and marketing. In the research and development area, Aerie Pharmaceuticals focuses on discovering and developing innovative therapeutics for the treatment of glaucoma and other eye diseases. One of the company's main products is Rhopressa (Netarsudil), a unique medication used to lower intraocular pressure in patients with glaucoma or ocular hypertension. Rhopressa belongs to a new class of drugs known as Rho kinase inhibitors, which have shown promising results in the treatment of eye diseases. In addition to Rhopressa, Aerie Pharmaceuticals has also developed a medication called Roclatan, a combination of Netarsudil and Latanoprost, used for the treatment of glaucoma and ocular hypertension. Both medications have the potential to lower intraocular pressure by up to 35%, significantly reducing the risk of vision loss in glaucoma patients. In the sales and marketing area, Aerie Pharmaceuticals works closely with physicians, pharmacies, and hospitals to position its products in the market and provide patients with access to the latest treatment options. The company has built a wide network of distribution partners and utilizes online platforms to promote its products and generate awareness. Aerie Pharmaceuticals follows a strategy of vertical integration, conducting both research and development and the marketing of its products in-house. This allows the company to bring its products to market faster and more effectively, offering its customers a higher value proposition. Overall, Aerie Pharmaceuticals is successful in the field of ophthalmology and has established itself as a key player in the industry. The company relies on innovation, research and development, and utilizes its expertise in sales and marketing to provide its customers with the best possible products and services.

What is the Aerie Pharmaceuticals dividend?

Aerie Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Aerie Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Aerie Pharmaceuticals or the company does not pay out a dividend.

What is the Aerie Pharmaceuticals ISIN?

The ISIN of Aerie Pharmaceuticals is US00771V1089.

What is the Aerie Pharmaceuticals WKN?

The WKN of Aerie Pharmaceuticals is A1W7RL.

What is the Aerie Pharmaceuticals ticker?

The ticker of Aerie Pharmaceuticals is AERI.

How much dividend does Aerie Pharmaceuticals pay?

Over the past 12 months, Aerie Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aerie Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aerie Pharmaceuticals?

The current dividend yield of Aerie Pharmaceuticals is .

When does Aerie Pharmaceuticals pay dividends?

Aerie Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aerie Pharmaceuticals?

Aerie Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aerie Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aerie Pharmaceuticals located?

Aerie Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aerie Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aerie Pharmaceuticals from 10/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/21/2024.

When did Aerie Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/21/2024.

What was the dividend of Aerie Pharmaceuticals in the year 2023?

In the year 2023, Aerie Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aerie Pharmaceuticals pay out the dividend?

The dividends of Aerie Pharmaceuticals are distributed in USD.

All fundamentals about Aerie Pharmaceuticals

Our stock analysis for Aerie Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aerie Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.